| Code | CSB-RA021334MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Lumistobart, targeting signal regulatory protein alpha (SIRPA, also known as CD172a). SIRPA is an inhibitory receptor expressed on myeloid cells, including macrophages and dendritic cells, that interacts with CD47 on target cells to deliver a "don't eat me" signal, thereby preventing phagocytosis. This immune checkpoint mechanism is frequently exploited by cancer cells that overexpress CD47, enabling tumor immune evasion. Disruption of the SIRPA-CD47 axis has emerged as a promising therapeutic strategy in oncology, particularly for hematologic malignancies and solid tumors that rely on macrophage evasion for survival.
Lumistobart is a clinical-stage therapeutic antibody designed to block the SIRPA-CD47 interaction, thereby promoting tumor cell phagocytosis and enhancing anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating SIRPA-mediated immune regulation, tumor-associated macrophage function, and innate immune checkpoint mechanisms. It supports studies exploring novel cancer immunotherapy approaches and understanding the role of myeloid cells in the tumor microenvironment.
There are currently no reviews for this product.